Gilead's coronavirus treatment remdesivir to cost $3,120 per U.S. patient with private insurance

Gilead Sciences announced Monday the much-anticipated pricing for its coronavirus treatment remdesivir, saying it will cost hospitals $3,120 for a typical U.S. patient with commercial insurance. The company announced its pricing plans in preparation for it to begin charging for the antiviral drug in July. The company has been donating doses to the U.S. government for distribution since it received emergency use authorization in May.
Read more: https://www.cnbc.com/2020/06/29/gileads-coronavirus-treatment-remdesivir-to-cost-3120-for-us-insured-patients.html?source=Snapzu